These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10318549)

  • 21. The endothelial cell and the factor VIII bypassing activity of prothrombin complex concentrate.
    Teitel JM; Ni HY; Freedman JJ; Garvey MB
    Thromb Haemost; 1988 Oct; 60(2):226-9. PubMed ID: 3146140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safe blood components for a hemophilia patient: a case report.
    Chuansumrit A; Pandhawong S; Tardtong P; Isarangkura P
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():198-200. PubMed ID: 7886573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and treatment of the hemophilias.
    Levin J
    Md State Med J; 1968 Sep; 17(9):75-7. PubMed ID: 5681701
    [No Abstract]   [Full Text] [Related]  

  • 24. Management of hemophilia in Spain.
    Martin-Villar J; Ortega F; Magallon M
    Thromb Haemost; 1976 Jun; 35(3):537-43. PubMed ID: 989959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in care of children with hemophilia.
    Manco-Johnson MJ; Riske B; Kasper CK
    Semin Thromb Hemost; 2003 Dec; 29(6):585-94. PubMed ID: 14719175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy.
    Youjin S; Jun Y
    Biotechnol Lett; 2009 Mar; 31(3):321-8. PubMed ID: 18979215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).
    Mansour-Ghanaei F; Fallah MS; Shafaghi A; Yousefi-Mashhoor M; Ramezani N; Farzaneh F; Nassiri R
    Med Sci Monit; 2002 Dec; 8(12):CR797-800. PubMed ID: 12503038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemophilia treatment: its relationship to blood products.
    Aledort LM; Goodnight SH
    Prog Hematol; 1981; 12():125-41. PubMed ID: 6803297
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
    Berntorp E
    Haematologica; 2003 Jun; 88(6):EREP03. PubMed ID: 12826529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitor to factor IX following activated prothrombin-complex concentrate treatment.
    Panicucci F; Sagripanti A; Conte B; Pinori E; Vispi M
    Thromb Haemost; 1981 Feb; 45(1):96. PubMed ID: 7245132
    [No Abstract]   [Full Text] [Related]  

  • 33. Factor products in the treatment of hemophilia.
    Miller KL
    J Pediatr Health Care; 2004; 18(3):156-7. PubMed ID: 15129219
    [No Abstract]   [Full Text] [Related]  

  • 34. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic choices for patients with hemophilia and high-titer inhibitors.
    Kulkarni R; Aledort LM; Berntorp E; Brackman HH; Brown D; Cohen AR; Ewing NP; Gringeri A; Gruppo R; Hoots K; Leissenger C; Peerlinck K; Poon MC; Wong WY
    Am J Hematol; 2001 Aug; 67(4):240-6. PubMed ID: 11443636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Products for clotting factor replacement in developing countries.
    Kasper CK
    Semin Thromb Hemost; 2005 Nov; 31(5):507-12. PubMed ID: 16276458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Successfull extirpation of femoral pseudotumour in a patient with severe haemophilia A and an inhibitor to factor VIII].
    Marisavljević D; Glisić M; Elezović I; Popović A; Rolović Z
    Srp Arh Celok Lek; 1991; 119(11-12):338-42. PubMed ID: 17974380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemorrhagic episodes in hemophiliacs simulating abdominal surgical emergencies.
    Rabie ME; Al-Tayeb AR; Zafer MH; Sheikha AK
    Saudi Med J; 2004 Jan; 25(1):95-8. PubMed ID: 14758390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood safety and the choice of anti-hemophilic factor concentrate.
    Janco RL
    Pediatr Blood Cancer; 2007 Jan; 48(1):117. PubMed ID: 17063470
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.